Product-related advice

• CMDh letter to MAHs of tenofovir disoproxil-containing medicinal products (February 2023, correction: June 2023)

• Q&As on the implementation of the outcome of the Art. 31 referral on angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (December 2021) [Tracked]

• Harmonised warning for ferrous sulfate-containing medicinal products on dysphagia and related bronchostenosis due to risk of aspiration (May 2018) [Tracked]

• Concomitant use of benzodiazepines/benzodiazepine like products and opioids (February 2018)

• CMDh letter for MAHs for medicinal products containing active ingredients in the form of Mesilates, Isetionates, Tosilates or Besilates (February 2008)

Deletion of interaction between broad spectrum antibiotics and combined oral contraceptives (COC)

• Public Assessment Report (March 2015) corrected in March 2016 [Tracked]
• List of ATC codes for which the change applies (January 2016)